Viewing data from:

PENTOXIFYLLINE

ANDA

PENTOXIFYLLINE | A074425 | RISING PHARMA HOLDING INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Pentoxifylline (2023)

Total Spending

$14.5M

Total Claims

359,916

Beneficiaries

88,717

Avg Cost/Unit

$0.37

Spending Trend

$11.2M(2019)→$12.0M(2020)→$12.1M(2021)→$13.7M(2022)→$14.5M(2023)

YoY Change:+6.8%

5yr CAGR:+8.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs8 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVPENTOXIFYLLINE USP

DMF 125621997

HIKAL LTDPENTOXIFYLLINE USP

DMF 141821999

SUN PHARMACEUTICAL INDUSTRIES LTDPENTOXIFYLLINE USP

DMF 149872000

ZAKLADY FARMACEUTYCZNE POLPHARMA SAPENTOXIFYLLINE

DMF 209762007

CSPC INNOVATION PHARM CO LTDPENTOXIFYLLINE

DMF 258992012

LABOCHIMInactivePENTOXIFYLLINE

DMF 64851986

DINAMITE DIPHARMA SPAInactivePENTOXIFYLLINE

DMF 76391988

ORION CORP LTDInactivePENTOXIFYLLINE

DMF 77031988

POLI INDUSTRIA CHIMICA SPAInactivePENTOXIFYLLINE

DMF 83241989

ZENTIVA ASInactivePENTOXIFYLLINE

DMF 103741993

PLANTEX LTDInactivePENTOXIFYLLINE

DMF 115491995

IPCA LABORATORIES LTDInactivePENTOXIFYLLINE

DMF 173452004

AUROBINDO PHARMA LTDInactivePENTOXIFYLLINE USP

DMF 182492005

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 400MG

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Jul 8, 1997

No patent or exclusivity listings for this strength.